The JI
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     
 


The Journal of Immunology, 2008, 180, 261-268
Copyright © 2008 by The American Association of Immunologists, Inc.

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Ding, J. W.
Right arrow Articles by Chong, A. S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Ding, J. W.
Right arrow Articles by Chong, A. S.

Hyperacute Rejection by Anti-Gal IgG1, IgG2a, and IgG2b Is Dependent on Complement and Fc-{gamma} Receptors1

Jin Wen Ding*, Tingting Zhou*, Huasong Zeng*, Lianli Ma*, J. Sjef Verbeek{dagger}, Dengping Yin*, Jikun Shen* and Anita S. Chong2,*

* Section of Transplantation, Department of Surgery, University of Chicago, Chicago, IL 60637; and {dagger} Department of Human Genetics, Leiden University Medical Center, Leiden, The Netherlands

We have previously reported that anti-Gal-{alpha}1,3Gal (Gal) IgG3 mAbs mediate a classical complement-dependent hyperacute rejection (HAR), while anti-Gal IgG1 mAbs mediate HAR that is dependent on complement, the Fc-{gamma} receptors Fc{gamma}RII/III (CD32/CD16), and NK cells. IgG2a and IgG2b subclasses can activate complement and have Fc{gamma}R binding properties in vitro. Whether these IgG subclasses can mediate HAR in vivo and the mechanisms by which they would do so are not known. In this study, we isolated spontaneous IgG switch mutants from an anti-Gal IgG1 hybridoma. In vitro complement-mediated hemolytic assays with mouse complement indicate that both anti-Gal IgG2a and IgG2b mAbs were more potent compared with the parent anti-Gal IgG1. In vivo administration of anti-Gal IgG2a and IgG2b mAbs into Gal–/– mice induced HAR of rat cardiac xenografts. HAR induced by anti-Gal IgG2a and IgG2b was dependent on complement activation and the presence of NK cells. Using Fc{gamma}RIII-deficient (Gal–/–CD16–/–) recipients, we observed that HAR mediated by different anti-Gal IgG subclasses was variably dependent on Fc{gamma}RIII, with IgG1 > IgG2b >> IgG2a = IgG3. Using Fc{gamma}RI-deficient (Gal–/–CD64–/–) recipients, we observed that HAR mediated by anti-Gal IgG1, IgG2a, and IgG2b, but not by anti-Gal IgG3, was dependent on Fc{gamma}RI. Collectively, these studies demonstrate the necessity and sufficiency of complement in IgG3-mediated HAR and the necessity of both complement and Fc{gamma}R, especially Fc{gamma}RI, in IgG1-, IgG2a-, and IgG2b-mediated HAR.

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

1 This work was supported by a grant from the National Institutes of Health (R01 AI52464) to A.S.C.

2 Address correspondence and reprint requests to Dr. Anita S. Chong, Department of Surgery, Section of Transplantation, MC5026, University of Chicago, Chicago, IL 60637. E-mail address: achong{at}uchicago.edu

3 Abbreviations used in this paper: HAR, hyperacute rejection; CVF, cobra venom factor; Gal, Gal-{alpha}1,3Gal; vWF, von Willebrand’s factor.




This article has been cited by other articles:


Home page
Cancer Res.Home page
T. Iuchi, S. Teitz-Tennenbaum, J. Huang, B. G. Redman, S. D. Hughes, M. Li, G. Jiang, A. E. Chang, and Q. Li
Interleukin-21 Augments the Efficacy of T-Cell Therapy by Eliciting Concurrent Cellular and Humoral Responses
Cancer Res., June 1, 2008; 68(11): 4431 - 4441.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
This Website Copyright © 2008 by The American Association of Immunologists, Inc. All rights reserved.
All Contents Copyright © 2008 by The American Association of Immunologists, Inc. All rights reserved.